Engineered cancer cells can fight primary and metastatic cancer

July 11, 2018, Brigham and Women's Hospital
In this image, CRISPR-engineered therapeutic cancer cells (green) track primary cancer cells (red) in the brain. Credit: CSTI/Khalid Shah lab

What if cancer cells could be re-engineered to turn against their own kind? A new study led by researchers at Brigham and Women's Hospital leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer. Results are published in Science Translational Medicine.

"This is just the tip of the iceberg," said corresponding author Khalid Shah MS, Ph.D., director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). "Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient's own and use them to treat . We think this has many implications and could be applicable across all cancer cell types."

The new approach capitalizes on cancer ' self-homing ability—the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.

The team developed and tested two techniques to harness the power of cancer cells. The "off the shelf" technique used pre-engineered tumor cells that would need to be matched to a patient's HLA phenotype (essentially, a person's immune fingerprint). The "autologous" approach used CRISPR technology to edit the genome of a patient's cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.

The CRISPR-engineered cancer cells (green) migrated towards an established glioblastoma tumor site (red) over the course of 28 days in a mouse model. Credit: C. Reinshagen et al., Science Translational Medicine (2018)

To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a "" that could be activated after treatment—PET imaging showed that this kill switch worked to eliminate the cells.

"Our study demonstrates the therapeutic potential of using engineered cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers," said Shah.

Explore further: How targeting metabolism can defeat cancer stem cells

More information: C. Reinshagen el al., "CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors," Science Translational Medicine (2018). stm.sciencemag.org/lookup/doi/ … scitranslmed.aao3240

Related Stories

How targeting metabolism can defeat cancer stem cells

July 3, 2018
Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment.

Stem cell-based therapy for targeting skin-to-brain cancer

July 10, 2017
Investigators from Brigham and Women's Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain. The team has developed cancer-killing viruses ...

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer

March 22, 2018
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development ...

Scientists isolate cancer stem cells using novel method

February 22, 2018
Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers—a significant step toward developing new drugs ...

New receptor genes turn T-cells into powerful liver cancer foes

April 3, 2018
Mouse genes that make human T cells powerful at fighting liver cancer could one day help patients do the same, scientists report.

Scientists engineer toxin-secreting stem cells to treat brain tumors

October 24, 2014
Harvard Stem Cell Institute scientists at Massachusetts General Hospital have devised a new way to use stem cells in the fight against brain cancer. A team led by neuroscientist Khalid Shah, MS, PhD, who recently demonstrated ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.